Logo image of SXTP

60 DEGREES PHARMA INC (SXTP) Stock Fundamental Analysis

NASDAQ:SXTP - Nasdaq - US83006G4010 - Common Stock - Currency: USD

3.16  -0.01 (-0.32%)

After market: 3.1975 +0.04 (+1.19%)

Fundamental Rating

2

SXTP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 197 industry peers in the Pharmaceuticals industry. The financial health of SXTP is average, but there are quite some concerns on its profitability. SXTP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SXTP has reported negative net income.
SXTP had a negative operating cash flow in the past year.
SXTP had negative earnings in each of the past 5 years.
SXTP had a negative operating cash flow in each of the past 5 years.
SXTP Yearly Net Income VS EBIT VS OCF VS FCFSXTP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -2M -4M -6M

1.2 Ratios

SXTP has a worse Return On Assets (-113.00%) than 79.19% of its industry peers.
SXTP has a worse Return On Equity (-138.85%) than 64.47% of its industry peers.
Industry RankSector Rank
ROA -113%
ROE -138.85%
ROIC N/A
ROA(3y)-277.62%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SXTP Yearly ROA, ROE, ROICSXTP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 -100 -200 -300 -400

1.3 Margins

The Gross Margin of SXTP (10.72%) is comparable to the rest of the industry.
The Profit Margin and Operating Margin are not available for SXTP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 10.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SXTP Yearly Profit, Operating, Gross MarginsSXTP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -500 -1K -1.5K -2K

More info and screens

4

2. Health

2.1 Basic Checks

SXTP does not have a ROIC to compare to the WACC, probably because it is not profitable.
SXTP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SXTP Yearly Shares OutstandingSXTP Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 1M 2M 3M 4M 5M
SXTP Yearly Total Debt VS Total AssetsSXTP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

SXTP has an Altman-Z score of -8.52. This is a bad value and indicates that SXTP is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -8.52, SXTP is not doing good in the industry: 70.56% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.02 indicates that SXTP is not too dependend on debt financing.
SXTP has a Debt to Equity ratio (0.02) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -8.52
ROIC/WACCN/A
WACC5.5%
SXTP Yearly LT Debt VS Equity VS FCFSXTP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 5.26 indicates that SXTP has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.26, SXTP is in the better half of the industry, outperforming 73.60% of the companies in the same industry.
A Quick Ratio of 4.91 indicates that SXTP has no problem at all paying its short term obligations.
The Quick ratio of SXTP (4.91) is better than 72.59% of its industry peers.
Industry RankSector Rank
Current Ratio 5.26
Quick Ratio 4.91
SXTP Yearly Current Assets VS Current LiabilitesSXTP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

3

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-228.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%440.86%

3.2 Future

The Earnings Per Share is expected to grow by 40.53% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 82.46% on average over the next years. This is a very strong growth
EPS Next Y77.95%
EPS Next 2Y40.53%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year109.78%
Revenue Next 2Y94.74%
Revenue Next 3Y82.46%
Revenue Next 5YN/A

3.3 Evolution

SXTP Yearly Revenue VS EstimatesSXTP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M
SXTP Yearly EPS VS EstimatesSXTP Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SXTP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SXTP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SXTP Price Earnings VS Forward Price EarningsSXTP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SXTP Per share dataSXTP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

A more expensive valuation may be justified as SXTP's earnings are expected to grow with 40.53% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.53%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SXTP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

60 DEGREES PHARMA INC

NASDAQ:SXTP (4/17/2025, 8:00:00 PM)

After market: 3.1975 +0.04 (+1.19%)

3.16

-0.01 (-0.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)N/A N/A
Inst Owners2.09%
Inst Owner Change0%
Ins Owners3.15%
Ins Owner Change9.31%
Market Cap4.65M
Analysts80
Price Target17.34 (448.73%)
Short Float %N/A
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-38.85%
Min EPS beat(2)-48.37%
Max EPS beat(2)-29.33%
EPS beat(4)1
Avg EPS beat(4)-7.57%
Min EPS beat(4)-72.17%
Max EPS beat(4)119.61%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-43.68%
Min Revenue beat(2)-45.31%
Max Revenue beat(2)-42.06%
Revenue beat(4)0
Avg Revenue beat(4)-35.64%
Min Revenue beat(4)-45.31%
Max Revenue beat(4)-11.04%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)400%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-355.68%
EPS NY rev (1m)-399.9%
EPS NY rev (3m)-399.9%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-22%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.04
P/FCF N/A
P/OCF N/A
P/B 0.77
P/tB 0.8
EV/EBITDA N/A
EPS(TTM)-39.64
EYN/A
EPS(NY)-8.74
Fwd EYN/A
FCF(TTM)-2.94
FCFYN/A
OCF(TTM)-2.77
OCFYN/A
SpS0.31
BVpS4.11
TBVpS3.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -113%
ROE -138.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 10.72%
FCFM N/A
ROA(3y)-277.62%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 549.44%
Cap/Sales 53.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.26
Quick Ratio 4.91
Altman-Z -8.52
F-Score3
WACC5.5%
ROIC/WACCN/A
Cap/Depr(3y)176.2%
Cap/Depr(5y)N/A
Cap/Sales(3y)19.34%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-228.7%
EPS Next Y77.95%
EPS Next 2Y40.53%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%440.86%
Revenue Next Year109.78%
Revenue Next 2Y94.74%
Revenue Next 3Y82.46%
Revenue Next 5YN/A
EBIT growth 1Y-90.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-335.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-349.79%
OCF growth 3YN/A
OCF growth 5YN/A